Anatomy Of A Medtech Carve-Out
Executive Summary
Divesting an underperforming and/or non-core asset could help reinvigorate a medtech business. But what are the issues that arise for the sellers of those assets, as well as the buyers, during the carve-out process? Jane Hobson and Phelim O'Doherty of Baker McKenzie discuss what the common issues are and how to address them in this guest column.